Skip to main content
. Author manuscript; available in PMC: 2018 Mar 13.
Published in final edited form as: Aliment Pharmacol Ther. 2017 Mar 8;45(9):1201–1212. doi: 10.1111/apt.14021

Figure 1.

Figure 1

Annual HCV regimens initiated (A), achieving SVR (observed) (B) and achieving SVR (observed and imputed) (C) with eras of HCV treatment regimens marked with dashed lines. Low HCV treatment and SVR levels during the pegylated interferon era (2001-2011) were followed by modest improvements during the boceprevir and telaprevir era (2011-2013) and much larger increases during the simeprevir and sofosbuvir (2014) and LDV/SOF and PrOD eras (2015).

The regimens shown include those with and without concomitant ribavirin.

Simeprevir + PEG regimens are not shown due to insufficient number of regimens initiated

A very small number of “SOF” regimens also included additional daclatasvir, which was approved on 7/24/15 for HCV genotype 3 infection.

PEG = pegylated-interferon

SOF = sofosbuvir

LDV/SOF = ledipasvir/sofosbuvir

PrOD = paritaprevir/ritonavir/ombitasvir/dasabuvir